Sanofi strengthens the case for I&I bispecifics with hidradenitis suppurativa data

Sanofi is building the case for bispecifics in inflammatory diseases with new data from a Phase II study of brivekimig for hidradenitis suppurativa suggesting that two targets may be better than one.

The pharma has been leading the charge in developing inflammation and immunology (I&I) bispecifics that intervene in multiple pathways to drive higher response rates and intercept resistance. On Wednesday, it reported that the dual-acting TNFα x OX40L nanobody led to one of the highest rates of symptom resolution seen in a Phase II trial in the indication to date...